Abstract Details

Title Application of ROBBIA in a Heterogeneous Multiple Sclerosis (MS) Cohort

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 112

Objective

Background BACKGROUND: ROBBIA is a "reaction time" (RT) research software program utilizing a computer stimulus screen and response box to investigate selective frontal attentional processes in association with focal and diffuse frontal lobe injury. The ROBBIA tasks minimize the multidimensional quality of tests commonly used to study frontal lobe cognitive processes and can potentially be used to study structure/function relationships in MS.

Design/Methods DESIGN/METHODS: 35 MS patients (11 early, 11 relapsing-remitting, and 13 secondary-progressive MS (SPMS)) were administered an abbreviated ROBBIA battery consisting of the simple, choice, prepare, and suppress tasks. Mean task RT (SE) is presented in graphical form. Performance differences between controls (n=25) and MS patients, and between MS subtypes, were investigated with Wilcoxon Rank Sum and Kruskal-Wallis tests.

Results RESULTS: Simple task: Patients were slower than controls (+97msec, p=.004), while SPMS was slower overall (p=.008). Early MS patients have disproportionately slower RT over successive trials. Choice task: No statistically significant RT difference among patients and between controls (+92msec, p=.07 to .26). No difference between accumulated errors (p=.26). Prepare task: SPMS patients were slower with an early and late warning stimulus (p=.01 to .05). Suppress task: SPMS patients were slower overall and by stimulus type (+277msec compared to controls, p=.02 to .04). Higher frequency distractor false positive errors trended for significance among patients (p=.10).

Conclusions CONCLUSIONS: Our preliminary data suggests that ROBBIA distinguishes MS from reference controls with task-specific worsening associated with disease progression. These findings may be related to selective involvement of frontal regions and is a testable hypothesis utilizing MRI metrics in the future. Investigation with a contemporary and age-matched control cohort is needed to confirm our preliminary results.

Authors/Disclosures
Allen S. Nielsen, MD (Kaiser Permanente-Fontana) PRESENTER	No disclosure on file
Revere P. Kinkel, MD, FAAN (University of California San Diego)	Dr. Kinkel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Kinkel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Kinkel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Kinkel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Kinkel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Kinkel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of Dr. Kinkel has received research support from Department of Defense. The institution of Dr. Kinkel has received research support from PCORI. The institution of Dr. Kinkel has received research support from Sanofi.
Michael V. Johnston, MD (Kennedy Krieger Institute)	No disclosure on file
Alexander U. Brandt, MD (Charite - Universitatsmedizin Berlin)	No disclosure on file

��ɫ��

��ɫ��